Search Results 1-10 of 16889 for hla genotype

  1. Selection of Allogeneic Hematopoietic Cell Donors Based on KIR and HLA Genotypes - Mayo Clinic

    Selection of Allogeneic Hematopoietic Cell Donors Based on KIR and HLA Genotypes · More about research at Mayo Clinic · Mayo Clinic Footer.

  2. Developing Antidrug Antibodies to Infliximab or Adalimumab in HLA DQ Alleles - Mayo Clinic

    ... HLA-DQ genotype. Participation eligibility. Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health ...

  3. Identification of Non-gal, Non-HLA Antigens in Patients Implanted with Xenogenic Material - Mayo Clinic

    The purpose of this study is to identify non-HLA and non-gal protein antigens in transplanted xenogenic tissues (ie bovine or porcine pericardial heart valves) ...

  4. Fractionated Anti HLA Antibodies Role in Prevention of Sold Organ Transplant Rejection - Mayo Clinic

    About this study. The purpose of this study is to develop single chain variable fragment antibodies against HLA A2 and test their efficacy in blocking the ...

  5. ... GENOTYPE,354,425, 300000024,HC ARPKD KNOWN MUTATION,480,480, 300000025,HC ... HLA CL I ABC TYPING HR,1094,1313, 300000178,HC HLA CL I ABC TYPING LR ...

  6. Daratumumab in Cardiac HLA Desensitization Prior to Transplantation - Mayo Clinic

    The objectives of this study is to evaluate the efficacy of Daratumumab as an HLA desensitization strategy prior to cardiac transplantation in highly-sensitized ...

  7. HLA-Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation With Reduced Dose Post Transplantation Cyclophosphamide GvHD Prophylaxis - Mayo Clinic

    About this study. The goal of this clinical trial is to determine the effectiveness of Reduced Dose Post-Transplant Cyclophosphamide (PTCy) in patients with ...

  8. Cellular Immunotherapy in Recipients of HLA-matched, Living Donor Kidney Transplants - Mayo Clinic

    The primary objective of this study is to demonstrate the safety and efficacy of cellular immunotherapy with MDR-101 for induction of functional immune ...

  9. A Phase 1 in Patients With HLA-A*0201+ and WT1+ Recurrent/Metastatic Cancers - Mayo Clinic

    A Phase 1 in Patients With HLA-A*0201+ and WT1+ Recurrent/Metastatic Cancers ... Patient must have HLA-A*0201 genotype as determined by genomic testing.

  10. Impact of Proteasome Inhibition on Anti-Donor HLA Antibody Production After Kidney Transplantation - Mayo Clinic

    The purpose of this study is to see if treating patients who have high levels of donor specific alloantibodies post-transplant with bortezomib might prevent the ...